Myriad Genetics Inc (NASDAQ:MYGN)

24.81
Delayed Data
As of May 22
 -0.95 / -3.69%
Today’s Change
24.61
Today|||52-Week Range
50.44
-14.65%
Year-to-Date
Why Should You Hold on to Myriad Genetics (MYGN) Stock?
May 21 / Zacks.comZAK - Paid Partner Content
Were Invitae's Quarterly Results Really That Bad?
May 09 / MotleyFool.com - Paid Partner Content
Myriad Genetics Reduced 2019 Guidance, but Is It Really So Bad?
May 15 / MotleyFool.com - Paid Partner Content
 

Today’s Trading

Previous close25.76
Today’s open25.61
Day’s range24.61 - 25.71
Volume692,109
Average volume (3 months)892,103
Market cap$1.9B
Data as of 4:00pm ET, 05/22/2019

Growth & Valuation

Earnings growth (last year)+490.63%
Earnings growth (this year)+40.23%
Earnings growth (next 5 years)+5.91%
Revenue growth (last year)+0.16%
P/E ratio88.5
Price/Sales3.48
Price/Book1.94

Competitors

 Today’s
change
Today’s
% change
--Quidel Corp-0.02-0.03%
QDELQuidel Corp+0.92+1.65%
CDNACareDx Inc-0.78-2.29%
VCYTVeracyte Inc+0.10+0.41%
Data as of 4:00pm ET, 05/22/2019

Financials

Next reporting dateAugust 22, 2019
EPS forecast (this quarter)$0.47
Annual revenue (last year)$772.6M
Annual profit (last year)$131.1M
Net profit margin16.97%

Profile

Sector
Health Technology
Industry
Biotechnology
President, Chief Executive Officer &
Director
Mark C. Capone
Executive Vice President-
International Operations
Gary A. King
Corporate headquarters
Salt Lake City, Utah

Forecasts